EA200602289A1 - Применение иматиниба для лечения нарушений работы печени и вирусных инфекций - Google Patents

Применение иматиниба для лечения нарушений работы печени и вирусных инфекций

Info

Publication number
EA200602289A1
EA200602289A1 EA200602289A EA200602289A EA200602289A1 EA 200602289 A1 EA200602289 A1 EA 200602289A1 EA 200602289 A EA200602289 A EA 200602289A EA 200602289 A EA200602289 A EA 200602289A EA 200602289 A1 EA200602289 A1 EA 200602289A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virus
treatment
imatiniba
disorders
liver
Prior art date
Application number
EA200602289A
Other languages
English (en)
Other versions
EA013813B1 (ru
Inventor
Филипп Ривьер
Марк Ривьер
Стефани Ридер
Original Assignee
Байоник Лайф Сайенсиз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200602289(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байоник Лайф Сайенсиз Инк. filed Critical Байоник Лайф Сайенсиз Инк.
Publication of EA200602289A1 publication Critical patent/EA200602289A1/ru
Publication of EA013813B1 publication Critical patent/EA013813B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Данное изобретение относится к применению иматиниба для лечения вирусных болезней печени и, в частности, вирусного гепатита. Изобретение предусматривает применение иматиниба для ингибирования репликации, переноса, или того и другого, вирусов гепатита. Далее, изобретение относится к применению иматиниба для ингибирования репликации, переноса, или того и другого, других вирусов, включая вирус герпеса, поксвирус, вирус гриппа, вирус парагриппа, респираторно-синцитиальный вирус, риновирус, вирус желтой лихорадки, западнонильский вирус и вирус энцефалита.
EA200602289A 2004-06-04 2005-06-03 Применение иматиниба для лечения гепатита с EA013813B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57657304P 2004-06-04 2004-06-04
PCT/CA2005/000869 WO2005117885A1 (en) 2004-06-04 2005-06-03 Use of imatinib to treat liver disorders and viral infections

Publications (2)

Publication Number Publication Date
EA200602289A1 true EA200602289A1 (ru) 2007-04-27
EA013813B1 EA013813B1 (ru) 2010-08-30

Family

ID=35462722

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200602289A EA013813B1 (ru) 2004-06-04 2005-06-03 Применение иматиниба для лечения гепатита с

Country Status (25)

Country Link
US (1) US8293745B2 (ru)
EP (1) EP1750713B1 (ru)
JP (1) JP5015769B2 (ru)
KR (1) KR101246863B1 (ru)
CN (2) CN1976709A (ru)
AP (1) AP2715A (ru)
AR (1) AR049141A1 (ru)
AU (1) AU2005249159A1 (ru)
BR (1) BRPI0511805A (ru)
CA (1) CA2568671A1 (ru)
DK (1) DK1750713T3 (ru)
EA (1) EA013813B1 (ru)
EC (1) ECSP055833A (ru)
ES (1) ES2397830T3 (ru)
IL (1) IL179796A0 (ru)
MA (1) MA28840B1 (ru)
MX (1) MXPA06014063A (ru)
MY (1) MY148676A (ru)
PE (1) PE20060399A1 (ru)
PL (1) PL1750713T3 (ru)
PT (1) PT1750713E (ru)
TN (1) TNSN06398A1 (ru)
TW (1) TWI393565B (ru)
UY (1) UY28942A1 (ru)
WO (1) WO2005117885A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005209231B8 (en) * 2004-01-21 2011-07-28 Emory University Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
CN102351842B (zh) 2005-11-25 2014-07-23 诺华股份有限公司 甲磺酸伊马替尼的f、g、h、i 和k晶形
JP5520479B2 (ja) 2006-02-20 2014-06-11 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、白色発光素子、及び照明装置
ES2535212T3 (es) * 2006-10-04 2015-05-06 Janssen Sciences Ireland Uc Carboxamido-4-[(4-piridil)amino]-pirimidinas para el tratamiento de la hepatitis C
US8435510B2 (en) 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
FR2923160B1 (fr) 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
JP2012503619A (ja) * 2008-09-26 2012-02-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｈｃｖ感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ
US20110236349A1 (en) * 2008-12-19 2011-09-29 Koff Jonathan L Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection
WO2012118599A1 (en) * 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication
WO2013024158A1 (en) * 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
KR101386697B1 (ko) * 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
US9487500B2 (en) * 2012-10-04 2016-11-08 Inhibikase Therapeutics, Inc. Compounds and compositions thereof
WO2017083971A1 (en) * 2015-11-16 2017-05-26 University Of Manitoba Compositions and methods for treatment of influenza
CN111481671A (zh) * 2020-05-26 2020-08-04 华中科技大学同济医学院附属协和医院 酪氨酸激酶抑制剂在制备系统性红斑狼疮脑病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527815B1 (en) * 1990-04-06 2000-07-19 Genelabs Technologies, Inc. Hepatitis c virus epitopes
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
WO2002010339A2 (en) * 2000-08-01 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Gene expression profile for kshv infection and methods for treating same
WO2002092573A2 (en) 2001-05-16 2002-11-21 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
US20050176687A1 (en) * 2001-06-29 2005-08-11 Alain Moussy Use of tyrosine kinase inhibitors for treating autoimmune diseases
NZ537156A (en) * 2002-05-23 2007-06-29 Cytopia Pty Ltd Kinase inhibitors
US7064127B2 (en) 2003-12-19 2006-06-20 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate
AU2005209231B8 (en) * 2004-01-21 2011-07-28 Emory University Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection

Also Published As

Publication number Publication date
BRPI0511805A (pt) 2008-01-15
PE20060399A1 (es) 2006-07-06
TWI393565B (zh) 2013-04-21
UY28942A1 (es) 2005-11-30
MA28840B1 (fr) 2007-09-03
ES2397830T3 (es) 2013-03-11
MY148676A (en) 2013-05-31
WO2005117885A1 (en) 2005-12-15
EA013813B1 (ru) 2010-08-30
US8293745B2 (en) 2012-10-23
CN1976709A (zh) 2007-06-06
JP5015769B2 (ja) 2012-08-29
KR20070051832A (ko) 2007-05-18
KR101246863B1 (ko) 2013-03-25
JP2008501646A (ja) 2008-01-24
EP1750713A4 (en) 2010-09-15
AP2006003863A0 (en) 2006-12-31
MXPA06014063A (es) 2007-04-25
PL1750713T3 (pl) 2013-04-30
CN102085202A (zh) 2011-06-08
IL179796A0 (en) 2007-05-15
US20060275260A1 (en) 2006-12-07
TW200602059A (en) 2006-01-16
CA2568671A1 (en) 2005-12-15
AU2005249159A1 (en) 2005-12-15
DK1750713T3 (da) 2013-02-11
AR049141A1 (es) 2006-06-28
EP1750713A1 (en) 2007-02-14
AP2715A (en) 2013-07-31
ECSP055833A (es) 2005-09-20
EP1750713B1 (en) 2012-10-17
TNSN06398A1 (en) 2008-02-22
PT1750713E (pt) 2013-01-25

Similar Documents

Publication Publication Date Title
EA200602289A1 (ru) Применение иматиниба для лечения нарушений работы печени и вирусных инфекций
ATE475660T1 (de) Antivirale verbindungen
WO2008133753A3 (en) Anti-viral compounds
WO2007081517A8 (en) Anti-viral compounds
IL192306A0 (en) Anti-viral compounds
EA200700243A1 (ru) Способы лечения гепатита с
NO20092585L (no) Forbindelser og farmasoytiske sammensetninger for behandling av virale infeksjoner
PA8588501A1 (es) Derivados antivirales de nucleósidos
NO20070751L (no) Inhibitorer av HCV-replifikasjon
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
ATE494373T2 (de) Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
EA201000556A1 (ru) Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
WO2009091388A3 (en) Triazines and related compounds having antiviral activity, compositions and methods thereof
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
WO2007025043A3 (en) Seven-membered ring nucleosides
WO2010021681A3 (en) Compositions and methods for treatment of viral diseases
WO2009136979A3 (en) Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
IL186730A0 (en) Cancer treatment using viruses, fluoropyrimidines and camptothecins
WO2005041951A3 (en) Rhodanine derivatives for use as antiviral agents
DK1765370T3 (da) Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS
WO2006043153A3 (en) Use of zinc and copper chelators for the treatment of viral diseases
NO20083034L (no) Farmasoytiske formuleringer av escitalopram med modifisert og pulserende frigivelse
NO20065582L (no) (1,lOB-dihydro-2-(amtnokarbonyl-fenyl)-SH-pyrazolo[1,5-C][1,3]benzoksazin-5-yl)fenylmetanonderivater som HIV-virusreplikasjonsinhibitorer
WO2005023270A3 (en) Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU